MedTrace Logo

The Comparative Effectiveness Between ARNI and ACE Inhibitor/ARB Medication in Patient With HFrEF

NCT05329727 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000000

Last updated 2023-08-01

No results posted yet for this study

Summary

This study aimed to evaluate the effectiveness, safety, and cost-effectiveness of ARNI and ACEi/ARBs in real-world practice. This study could find out what the unmet medical needs are in real world practice. Furthermore, this study will be helpful to establish the healthcare policy reimbursement policy or clinical practice guideline for HF regarding HF medications to reduce the burden of HF in Korea.

Conditions

Interventions

DRUG

Angiotensin receptor neprilysin inhibitor (ARNI)

The group with ARNI was defined as patients with HFrEF took ARNI more than 3 months

DRUG

Renin-Angiotensin System Inhibitor (RAS inhibitor)

The group with RAS inhibitor was defined as patients with HFrEF took RAS inhibitor more than 3 months

Sponsors & Collaborators

  • Wonju Severance Christian Hospital

    lead OTHER

Principal Investigators

  • Byung Su Yoo, MD,PhD · Yonsei Wonju Christian Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-18
Primary Completion
2022-06-30
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05329727 on ClinicalTrials.gov